Depression

Neurology·MeSH: Depression

Prevalence

3062.9 / 100K

Incidence

3754.6 / 100K/yr

51 drugs in development·36 companies·59 clinical trials

Drug Pipeline by Phase

Approved(12)

Drug	Company
Caplyta	Intra-Cellular Therapies, Inc. (ITCI)
imipramine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
inFoods® (IBS)	BIOMERICA INC (BMRA)
lurasidone	DR REDDYS LABORATORIES LTD (RDY)
neurostar advanced therapy system	Neuronetics Inc. (STIM)
rextovy	Amphastar Pharmaceuticals, Inc. (AMPH)
siberian ginseng series	Fuss Brands Corp. (FBDS)
trimipramine	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
venlafaxine	Teva Pharmaceutical Industries Limited (TEVA)
ZULRESSO	Sage Therapeutics, Inc. (SAGE)
ZURZUVAE	BIOGEN INC. (BIIB)
ZURZUVAE	Sage Therapeutics, Inc. (SAGE)

Phase 3(6)

Drug	Company
azetukalner	Xenon Pharmaceuticals Inc. (XENE)
cariprazine	AbbVie Inc. (ABBV)
COMP360 psilocybin treatment	COMPASS Pathways plc (CMPS)
lpcn 1154a	Lipocine Inc. (LPCN)
nrx-100	NRX Pharmaceuticals Inc. (NRXP)
psilocybin	GH Research PLC (GHRS)

Phase 2(11)

Drug	Company
ALTO-100	Alto Neuroscience, Inc. (ANRO)
ALTO-101	Alto Neuroscience, Inc. (ANRO)
ALTO-202	Alto Neuroscience, Inc. (ANRO)
alto-207	Alto Neuroscience, Inc. (ANRO)
ALTO-300	Alto Neuroscience, Inc. (ANRO)
BPL-003	Atai Beckley N.V. (ATAI)
nv-5138	SUPERNUS PHARMACEUTICALS, INC. (SUPN)
nv-5138	X4 Pharmaceuticals, Inc (XFOR)
Psilly	AIBOTICS, INC. (AIBT)
Psilocybin	COMPASS Pathways plc (CMPS)
VLS-01	Atai Beckley N.V. (ATAI)

Phase 1(1)

Drug	Company
ketamir-2	MIRA PHARMACEUTICALS, INC. (MIRA)

Preclinical(12)

Drug	Company
ART12.11	ARTELO BIOSCIENCES, INC. (ARTL)
cannabis oil	ALGAE DYNAMICS CORP. (ADYNF)
curefilm central nervous system	AVENIR WELLNESS SOLUTIONS, INC. (CURR)
cyc-126	Cyclerion Therapeutics, Inc. (CYCN)
EGX-A and EGX-B	Atai Beckley N.V. (ATAI)
htx-100	NRX Pharmaceuticals Inc. (NRXP)
individualized therapy for trd	Cyclerion Therapeutics, Inc. (CYCN)
kv7 development candidates	Xenon Pharmaceuticals Inc. (XENE)
psilocin pro	INNOVATION1 BIOTECH INC. (GMVP)
salvinorin a film	INTELGENX TECHNOLOGIES CORP. (IGXT)
supera-cbd	Q/C TECHNOLOGIES, INC. (QCLS)
vls-01	INTELGENX TECHNOLOGIES CORP. (IGXT)

Unknown(5)

Drug	Company
dario mind	DarioHealth Corp. (DRIO)
GeneSight	MYRIAD GENETICS INC (MYGN)
InFoods® platform (other disease targets)	BIOMERICA INC (BMRA)
Medical formulations portfolio	Cannabis Bioscience International Holdings, Inc. (CBIH)
Xpro1595/INB03	Xencor Inc (XNCR)

BLA Filed(1)

Drug	Company
ketafree	NRX Pharmaceuticals Inc. (NRXP)

Phase 1/Phase 2(1)

Drug	Company
ABV-1601	ABVC BIOPHARMA, INC. (ABVC)

Phase 2/Phase 3(2)

Drug	Company
js1-1-01 high-dose group	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
js1-1-01 low-dose group	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

BioSniper tracks 51 drugs in development for Depression across 36 companies.

There are 59 clinical trials targeting Depression tracked by BioSniper.

The estimated prevalence of Depression is approximately 3062.9 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.